Recombinant AAV-directed gene therapy for type I glycogen storage diseases - PubMed Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Aug;11(8):1011-24.
doi: 10.1517/14712598.2011.578067. Epub 2011 Apr 20.

Recombinant AAV-directed gene therapy for type I glycogen storage diseases

Janice Y Chou  1 , Brian C Mansfield
Affiliations
Review

Recombinant AAV-directed gene therapy for type I glycogen storage diseases

Janice Y Chou et al. Expert Opin Biol Ther. 2011 Aug.

Abstract

Introduction: Glycogen storage disease (GSD) type Ia and Ib are disorders of impaired glucose homeostasis affecting the liver and kidney. GSD-Ib also affects neutrophils. Current dietary therapies cannot prevent long-term complications. In animal studies, recombinant adeno-associated virus (rAAV) vector-mediated gene therapy can correct or minimize multiple aspects of the disorders, offering hope for human gene therapy.

Areas covered: A summary of recent progress in rAAV-mediated gene therapy for GSD-I; strategies to improve rAAV-mediated gene delivery, transduction efficiency and immune avoidance; and vector refinements that improve expression.

Expert opinion: rAAV-mediated gene delivery to the liver can restore glucose homeostasis in preclinical models of GSD-I, but some long-term complications of the liver and kidney remain. Gene therapy for GSD-Ib is less advanced than for GSD-Ia and only transient correction of myeloid dysfunction has been achieved. A question remains as to whether a single rAAV vector can meet the expression efficiency and tropism required to treat all aspects of GSD-I, or if a multi-pronged approach is needed. An understanding of the strengths and weaknesses of rAAV vectors in the context of strategies to achieve efficient transduction of the liver, kidney and hematopoietic stem cells is required for treating GSD-I.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The G6Pase-α/G6PT complex maintains interprandial glucose homeostasis. G6Pase-α and G6PT are shown anchored in the membrane of the ER in contact with both the cytoplasm and ER lumen. The catalytic site of G6Pase-α lies in the ER lumen and the amino acids participating in G6Pase-α catalysis are highlighted. The spatial representations are illustrative only, for the complexes to be active, G6Pase-α must couple functionally with G6PT.
Figure 2
Figure 2
GSD-Ia and GSD-Ib manifest overlapping, yet distinct, phenotypes.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chou JY, Matern D, Mansfield BC, et al. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med. 2002;2:121–143. - PubMed
    1. Chou JY, Jun HS, Mansfield BC. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Nat Rev Endocrinol. 2010;6:676–688. - PMC - PubMed
    1. Lei K-J, Pan C-J, Shelly LL, et al. Identification of mutations in the gene for glucose-6-phosphatase, the enzyme deficient in glycogen storage disease type 1a. J Clin Invest. 1994;93:1994–1999. - PMC - PubMed
    1. Lei K-J, Shelly LL, Pan C-J, et al. Mutations in the glucose-6-phosphatase gene that cause glycogen storage disease type 1a. Science. 1993;262:580–583. - PubMed
    1. Pan C-J, Lei K-J, Annabi B, et al. Transmembrane topology of glucose-6-phosphatase. J Biol Chem. 1998;273:6144–6148. - PubMed

Publication types